<?xml version="1.0" encoding="UTF-8"?>
<html lang="en" dir="ltr" xmlns="http://www.w3.org/1999/xhtml">
 <head prefix="og: http://ogp.me/ns# article: http://ogp.me/ns/article# book: http://ogp.me/ns/book#"> 
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/> 
  <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=3, minimum-scale=1, user-scalable=yes"/> 
  <meta name="type" content="article"/>
  <meta name="HW.identifier" content="/biorxiv/early/2020/04/12/2020.04.10.036418.atom"/>
  <meta name="HW.pisa" content="biorxiv;2020.04.10.036418v1"/>
  <meta name="DC.Format" content="text/html"/>
  <meta name="DC.Language" content="en"/>
  <meta name="DC.Title" content="The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement"/>
  <meta name="DC.Identifier" content="10.1101/2020.04.10.036418"/>
  <meta name="DC.Date" content="2020-04-12"/>
  <meta name="DC.Publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="DC.Rights" content="© 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/"/>
  <meta name="DC.AccessRights" content="restricted"/>
  <meta name="DC.Description" content="The SARS-coronavirus 2 (SARS-CoV-2) spike (S) protein mediates entry of SARS-CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The S protein engages ACE2 through its receptor-binding domain (RBD), an independently folded 197-amino acid fragment of the 1273-amino acid S-protein protomer. Antibodies to the RBD domain of SARS-CoV (SARS-CoV-1), a closely related coronavirus which emerged in 2002-2003, have been shown to potently neutralize SARS-CoV-1 S-protein-mediated entry, and the presence of anti-RBD antibodies correlates with neutralization in SARS-CoV-2 convalescent sera. Here we show that immunization with the SARS-CoV-2 RBD elicits a robust neutralizing antibody response in rodents, comparable to 100 μg/ml of ACE2-Ig, a potent SARS-CoV-2 entry inhibitor. Importantly, anti-sera from immunized animals did not mediate antibody-dependent enhancement (ADE) of S-protein-mediated entry under conditions in which Zika virus ADE was readily observed. These data suggest that an RBD-based vaccine for SARS-CoV-2 could be safe and effective. ### Competing Interest Statement The authors have declared no competing interest."/>
  <meta name="DC.Contributor" content="Brian D Quinlan"/>
  <meta name="DC.Contributor" content="Huihui Mou"/>
  <meta name="DC.Contributor" content="Lizhou Zhang"/>
  <meta name="DC.Contributor" content="Yan Gao"/>
  <meta name="DC.Contributor" content="Wenhui He"/>
  <meta name="DC.Contributor" content="Amrita Ojha"/>
  <meta name="DC.Contributor" content="Mark S Parcells"/>
  <meta name="DC.Contributor" content="Guangxiang Luo"/>
  <meta name="DC.Contributor" content="Wenhui Li"/>
  <meta name="DC.Contributor" content="Guocai Zhong"/>
  <meta name="DC.Contributor" content="Hyeryun Choe"/>
  <meta name="DC.Contributor" content="Michael Farzan"/>
  <meta name="article:published_time" content="2020-04-12"/>
  <meta name="article:section" content="New Results"/>
  <meta name="citation_title" content="The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement"/>
  <meta name="citation_abstract" lang="en" content="&lt;;p&gt;;The SARS-coronavirus 2 (SARS-CoV-2) spike (S) protein mediates entry of SARS-CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The S protein engages ACE2 through its receptor-binding domain (RBD), an independently folded 197-amino acid fragment of the 1273-amino acid S-protein protomer. Antibodies to the RBD domain of SARS-CoV (SARS-CoV-1), a closely related coronavirus which emerged in 2002-2003, have been shown to potently neutralize SARS-CoV-1 S-protein-mediated entry, and the presence of anti-RBD antibodies correlates with neutralization in SARS-CoV-2 convalescent sera. Here we show that immunization with the SARS-CoV-2 RBD elicits a robust neutralizing antibody response in rodents, comparable to 100 μg/ml of ACE2-Ig, a potent SARS-CoV-2 entry inhibitor. Importantly, anti-sera from immunized animals did not mediate antibody-dependent enhancement (ADE) of S-protein-mediated entry under conditions in which Zika virus ADE was readily observed. These data suggest that an RBD-based vaccine for SARS-CoV-2 could be safe and effective.&lt;;/p&gt;;"/>
  <meta name="citation_journal_title" content="bioRxiv"/>
  <meta name="citation_publisher" content="Cold Spring Harbor Laboratory"/>
  <meta name="citation_publication_date" content="2020/01/01"/>
  <meta name="citation_mjid" content="biorxiv;2020.04.10.036418v1"/>
  <meta name="citation_id" content="2020.04.10.036418v1"/>
  <meta name="citation_public_url" content="https://www.biorxiv.org/content/10.1101/2020.04.10.036418v1"/>
  <meta name="citation_abstract_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.10.036418v1.abstract"/>
  <meta name="citation_full_html_url" content="https://www.biorxiv.org/content/10.1101/2020.04.10.036418v1.full"/>
  <meta name="citation_pdf_url" content="https://www.biorxiv.org/content/biorxiv/early/2020/04/12/2020.04.10.036418.full.pdf"/>
  <meta name="citation_doi" content="10.1101/2020.04.10.036418"/>
  <meta name="citation_section" content="New Results"/>
  <meta name="citation_firstpage" content="2020.04.10.036418"/>
  <meta name="citation_author" content="Brian D Quinlan"/>
  <meta name="citation_author_institution" content="The Scripps Research Institute;"/>
  <meta name="citation_author_email" content="bquinlan@scripps.edu"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0003-2719-731X"/>
  <meta name="citation_author" content="Huihui Mou"/>
  <meta name="citation_author_institution" content="The Scripps Research Institute;"/>
  <meta name="citation_author" content="Lizhou Zhang"/>
  <meta name="citation_author_institution" content="The Scripps Research Institute;"/>
  <meta name="citation_author" content="Yan Gao"/>
  <meta name="citation_author_institution" content="The Scripps Research Institute;"/>
  <meta name="citation_author" content="Wenhui He"/>
  <meta name="citation_author_institution" content="The Scripps Research Institute;"/>
  <meta name="citation_author" content="Amrita Ojha"/>
  <meta name="citation_author_institution" content="The Scripps Research Institute;"/>
  <meta name="citation_author" content="Mark S Parcells"/>
  <meta name="citation_author_institution" content="University of Delaware;"/>
  <meta name="citation_author" content="Guangxiang Luo"/>
  <meta name="citation_author_institution" content="University of Alabama;"/>
  <meta name="citation_author" content="Wenhui Li"/>
  <meta name="citation_author_institution" content="National Institute of Biological Sciences;"/>
  <meta name="citation_author" content="Guocai Zhong"/>
  <meta name="citation_author" content="Hyeryun Choe"/>
  <meta name="citation_author_institution" content="The Scripps Research Institute;"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0003-4538-7176"/>
  <meta name="citation_author" content="Michael Farzan"/>
  <meta name="citation_author_institution" content="The Scripps Research Institute;"/>
  <meta name="citation_author_email" content="mfarzan@scripps.edu"/>
  <meta name="citation_author_orcid" content="http://orcid.org/0000-0002-2990-5319"/>
  <meta name="twitter:title" content="The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement"/>
  <meta name="twitter:site" content="@biorxivpreprint"/>
  <meta name="twitter:card" content="summary"/>
  <meta name="twitter:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="twitter:description" content="The SARS-coronavirus 2 (SARS-CoV-2) spike (S) protein mediates entry of SARS-CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The S protein engages ACE2 through its receptor-binding domain (RBD), an independently folded 197-amino acid fragment of the 1273-amino acid S-protein protomer. Antibodies to the RBD domain of SARS-CoV (SARS-CoV-1), a closely related coronavirus which emerged in 2002-2003, have been shown to potently neutralize SARS-CoV-1 S-protein-mediated entry, and the presence of anti-RBD antibodies correlates with neutralization in SARS-CoV-2 convalescent sera. Here we show that immunization with the SARS-CoV-2 RBD elicits a robust neutralizing antibody response in rodents, comparable to 100 μg/ml of ACE2-Ig, a potent SARS-CoV-2 entry inhibitor. Importantly, anti-sera from immunized animals did not mediate antibody-dependent enhancement (ADE) of S-protein-mediated entry under conditions in which Zika virus ADE was readily observed. These data suggest that an RBD-based vaccine for SARS-CoV-2 could be safe and effective. ### Competing Interest Statement The authors have declared no competing interest."/>
  <meta name="og-title" property="og:title" content="The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement"/>
  <meta name="og-url" property="og:url" content="https://www.biorxiv.org/content/10.1101/2020.04.10.036418v1"/>
  <meta name="og-site-name" property="og:site_name" content="bioRxiv"/>
  <meta name="og-description" property="og:description" content="The SARS-coronavirus 2 (SARS-CoV-2) spike (S) protein mediates entry of SARS-CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The S protein engages ACE2 through its receptor-binding domain (RBD), an independently folded 197-amino acid fragment of the 1273-amino acid S-protein protomer. Antibodies to the RBD domain of SARS-CoV (SARS-CoV-1), a closely related coronavirus which emerged in 2002-2003, have been shown to potently neutralize SARS-CoV-1 S-protein-mediated entry, and the presence of anti-RBD antibodies correlates with neutralization in SARS-CoV-2 convalescent sera. Here we show that immunization with the SARS-CoV-2 RBD elicits a robust neutralizing antibody response in rodents, comparable to 100 μg/ml of ACE2-Ig, a potent SARS-CoV-2 entry inhibitor. Importantly, anti-sera from immunized animals did not mediate antibody-dependent enhancement (ADE) of S-protein-mediated entry under conditions in which Zika virus ADE was readily observed. These data suggest that an RBD-based vaccine for SARS-CoV-2 could be safe and effective. ### Competing Interest Statement The authors have declared no competing interest."/>
  <meta name="og-type" property="og:type" content="article"/>
  <meta name="og-image" property="og:image" content="https://www.biorxiv.org/sites/default/files/images/biorxiv_logo_homepage7-5-small.png"/>
  <meta name="citation_date" content="2020-04-12"/> 
  <meta name="description" content="bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution"/>
  <meta name="generator" content="Drupal 7 (http://drupal.org)"/> 
  <title>The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement | bioRxiv</title> 
 </head>
 <body class="html not-front not-logged-in page-node page-node- page-node-1240395 node-type-highwire-article context-content hw-default-jcode-biorxiv hw-article-category-new-results"> 
  <div class="article abstract-view ">
   <span class="highwire-journal-article-marker-start"/>
   <div class="section abstract" id="abstract-1">
    <h2>Abstract</h2>
    <p id="p-2">The SARS-coronavirus 2 (SARS-CoV-2) spike (S) protein mediates entry of SARS-CoV-2 into cells expressing the angiotensin-converting enzyme 2 (ACE2). The S protein engages ACE2 through its receptor-binding domain (RBD), an independently folded 197-amino acid fragment of the 1273-amino acid S-protein protomer. Antibodies to the RBD domain of SARS-CoV (SARS-CoV-1), a closely related coronavirus which emerged in 2002-2003, have been shown to potently neutralize SARS-CoV-1 S-protein-mediated entry, and the presence of anti-RBD antibodies correlates with neutralization in SARS-CoV-2 convalescent sera. Here we show that immunization with the SARS-CoV-2 RBD elicits a robust neutralizing antibody response in rodents, comparable to 100 μg/ml of ACE2-Ig, a potent SARS-CoV-2 entry inhibitor. Importantly, anti-sera from immunized animals did not mediate antibody-dependent enhancement (ADE) of S-protein-mediated entry under conditions in which Zika virus ADE was readily observed. These data suggest that an RBD-based vaccine for SARS-CoV-2 could be safe and effective.</p>
   </div>
   <h3>Competing Interest Statement</h3>
   <p id="p-3">The authors have declared no competing interest.</p>
   <span class="highwire-journal-article-marker-end"/>
  </div>
 </body>
</html>
